| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CLR (Calcitonin receptor-like receptor) in complex with RAMP2 or RAMP3.
|
|---|---|
| ln Vitro |
In order to investigate the impact of Adrenomedullin(AM)(1-52), human on astroglioma cells, CRT-MG cells are cultured for 48 hours in a medium containing 1% FBS, either in the presence or absence of Adrenomedullin(AM)(1-52), human (ADM1-52). The wound-healing experiment is then conducted. Compared to the untreated cells, the ADM1-52-treated cells exhibit a dose-dependent increase in the number of cells moving to the wound region[1].
Adrenomedullin (1-52) stimulates cell proliferation and migration in endothelial cells and influences cancer cell behavior. It activates downstream signaling pathways including cAMP production, nitric oxide (NO) synthesis, and MAP kinase activation in target cells. |
| ln Vivo |
In vivo, Adrenomedullin is a potent vasodilator, inducing a rapid and sustained decrease in mean arterial blood pressure. It also possesses angiogenic properties, promoting the formation of new blood vessels, which is a critical process in both wound healing and tumor progression.
|
| Enzyme Assay |
For a receptor binding assay, membranes from cells expressing human CLR/RAMP2 are incubated with [125I]-Adrenomedullin. Unlabeled Adrenomedullin is added to compete for binding. After incubation, bound ligand is separated by filtration and counted. Ki values are calculated from competition curves.
|
| Cell Assay |
Human umbilical vein endothelial cells (HUVECs) are seeded on Matrigel and treated with Adrenomedullin. Tube formation is observed and quantified after 6-12 hours. Alternatively, cells are treated, and intracellular cAMP levels are measured using a competitive ELISA to confirm receptor activation.
|
| Animal Protocol |
To measure vascular permeability, Miles assays are performed. Intradermal injection of Evans blue dye and peptide is given in the back skin of mice. Extravasation of dye into the skin (blue spots) is measured spectrophotometrically after extraction with formamide.
|
| ADME/Pharmacokinetics |
As a 52-amino acid peptide, Adrenomedullin (1-52) has a very short half-life (a few minutes) in circulation due to rapid degradation by proteases. It is primarily cleared by the kidneys. For in vivo studies, continuous infusion is often used to maintain stable plasma levels.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is reported for this research peptide. At high doses, the vasodilatory effects can cause profound hypotension (shock). Chronic overexpression or exposure may contribute to pathological angiogenesis, e.g., in cancer or diabetic retinopathy.
|
| References |
[1]. Lim SY, et al. Transcriptional regulation of adrenomedullin by oncostatin M in human astroglioma cells: implications for tumor invasion and migration. Sci Rep. 2014 Sep 23;4:6444.
|
| Additional Infomation |
Adrenomedullin was initially isolated from human pheochromocytoma (a tumor of the adrenal medulla). It is involved in a wide range of physiological processes, including cardiovascular homeostasis, pregnancy, and host defense. Its expression is elevated in various cancers and contributes to the proliferation and survival of malignant cells. This product is for research use only, not clinical.
|
| Molecular Formula |
C266H407F3N80O79S3
|
|---|---|
| Molecular Weight |
6142.76
|
| Related CAS # |
Adrenomedullin (AM) (1-52), human;148498-78-6
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~25 mg/mL (~4.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1628 mL | 0.8140 mL | 1.6279 mL | |
| 5 mM | 0.0326 mL | 0.1628 mL | 0.3256 mL | |
| 10 mM | 0.0163 mL | 0.0814 mL | 0.1628 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
